QQ客服 官方微博 反馈留言

	BMI as Factor Predicting the Efficacy of Gefitinib in NSCLC with EGFR Mutation
	Sun Hongyan; Sun Xiaoteng; Zhai Xiaoyu; Guo Jingfeng; Liu Yutao; Ying Jianming; Wang Ziping
	2015
卷号	10期号:9页码:S528-S529
关键词	classification and regression tree (CART) non-small-cell lung cancer (NSCLC) EGFR active mutation body mass index (BMI)
ISSN号	1556-0864
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6663240
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Sun Hongyan,Sun Xiaoteng,Zhai Xiaoyu,et al. BMI as Factor Predicting the Efficacy of Gefitinib in NSCLC with EGFR Mutation[J],2015,10(9):S528-S529.
APA	Sun Hongyan.,Sun Xiaoteng.,Zhai Xiaoyu.,Guo Jingfeng.,Liu Yutao.,...&Wang Ziping.(2015).BMI as Factor Predicting the Efficacy of Gefitinib in NSCLC with EGFR Mutation.,10(9),S528-S529.
MLA	Sun Hongyan,et al."BMI as Factor Predicting the Efficacy of Gefitinib in NSCLC with EGFR Mutation".10.9(2015):S528-S529.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。